KIF1A

APRIL 13, 2024

#ScienceSaturday posts share exciting scientific developments and educational resources with the KAND community. Each week, Dr. Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. KIF1A-Related Research Clinical exome sequencing uncovers genetic disorders in neonates with suspected hypoxic–ischemic encephalopathy: A retrospective analysis Brain injuries and developmental disorders can be difficu

Disease 111

Disease Research Science 111

Drug Patent Watch

APRIL 13, 2024

DEXILANT SOLUTAB (dexlansoprazole) Takeda pharms usa Patent: 8,784,885 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… Source

Pharmaceuticals 59

Pharmaceuticals Drugs 59

Perficient: Drug Development

APRIL 13, 2024

Introduction: Despite the scorching heat of Hyderabad, the spirit of sportsmanship prevailed throughout the week as our organisational cricket and table tennis tournaments unfolded. Over the course of several days, teams battled it out on the cricket field, while table tennis enthusiasts showcased their skills within the office premises. With each passing day, the excitement and anticipation grew, culminating in memorable moments of triumph and companionship.

52

52

Drug Patent Watch

APRIL 13, 2024

This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Drug Patent Watch

APRIL 13, 2024

Annual Drug Patent Expirations for ADVAIR+HFA Advair Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from three suppliers.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 13, 2024

Annual Drug Patent Expirations for VOSEVI Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier.

Science 52

Science Drugs Marketing 52

Drug Patent Watch

APRIL 13, 2024

Annual Drug Patent Expirations for DAURISMO Daurismo is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 13, 2024

Annual Drug Patent Expirations for XOSPATA Xospata is a drug marketed by Astellas and is included in one NDA. It is available from one supplier.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

APRIL 13, 2024

Annual Drug Patent Expirations for TYRVAYA Tyrvaya is a drug marketed by Oyster Point Pharma and is included in one NDA. It is available from one supplier.

Drugs 52

Drugs Marketing 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Patent Watch

APRIL 13, 2024

Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. It is available from one supplier.

Drugs 52

Drugs Marketing 52